一种强效和选择性的TNKS2抑制剂,用于瘤选择性WNT抑制
Jill Zimmerman1,2, Brandon F Malone3, Efrat Finkin-Groner4
1Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, 10021.
bioRxiv : the preprint server for biology
|March 17, 2025
概括
染色体8p丢失的瘤对基酶2 (TNKS2) 抑制具有脆弱性. 这允许在癌细胞中选择性抑制WNT通路,为表皮性恶性瘤提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 过度活跃的WNT信号驱动癌症,但WNT抑制剂面临毒性问题.
- 坦基拉酶 (TNKS) 抑制剂可以抑制WNT信号传递,但缺乏瘤选择性.
- 现有的TNKS抑制剂影响瘤和健康组织,限制了临床使用.
研究的目的:
- 确定一种选择性瘤方法来抑制WNT信号传递.
- 调查染色体8p损失在产生坦基拉酶抑制的脆弱性中的作用.
- 开发一种TNKS2选择性抑制剂,用于向抑制癌症中的WNT通路.
主要方法:
- 在晚期上皮质恶性瘤中分析8p染色体损失.
- 评估与8p损失相关的坦基酶1 (TNKS1) 和坦基酶2 (TNKS2) 表达.
- 结构导向药物设计以识别TNKS2选择性抑制剂.
- 在TNKS1缺乏的癌细胞和有机体模型中测试该抑制剂.
主要成果:
- 在上皮癌中常见的8p染色体损失导致TNKS1耗尽.
- 这种8p的损失产生了对TNKS2蛋白的瘤特异性依赖.
- 发现了一种新型的,第一类的TNKS2选择性抑制剂.
- 抑制剂在TNKS1缺乏的癌症模型中选择性地抑制了WNT信号传递.
结论:
- 染色体8p损失代表了多种癌症类型的可针对性脆弱性.
- 选择性抑制TNKS2提供了一种强效和选择性WNT向癌症治疗的策略.
- 这种方法可以克服与更广泛的WNT抑制剂相关的目标毒性问题.
相关概念视频
Canonical Wnt Signaling Pathway
8.6K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.6K
Non-Canonical Wnt Signaling Pathways
7.2K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Loss of Tumor Suppressor Gene Functions
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


